glioblastoma Gene Set

Dataset Phosphosite Textmining Biological Term Annotations
Category structural or functional annotations
Type biological term
Description The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO)|Glial cell derived tumors arising from the optic nerve, usually presenting in childhood. Roughly 50% are associated with NEUROFIBROMATOSIS 1. Clinical manifestations include decreased visual acuity; EXOPHTHALMOS; NYSTAGMUS, PATHOLOGIC; STRABISMUS; pallor or swelling of the optic disc; and INTRACRANIAL HYPERTENSION. The tumor may extend into the optic chiasm and hypothalamus (MeSH).|A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures (MeSH).|A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. (Experimental Factor Ontology, EFO_0000519)
Similar Terms
Downloads & Tools

Genes

78 proteins co-occuring with the biological term glioblastoma in abstracts of publications describing phosphosites from the Phosphosite Textmining Biological Term Annotations dataset.

Symbol Name
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase
ABL2 ABL proto-oncogene 2, non-receptor tyrosine kinase
ACACA acetyl-CoA carboxylase alpha
AGAP2 ArfGAP with GTPase domain, ankyrin repeat and PH domain 2
AKT1 v-akt murine thymoma viral oncogene homolog 1
ATF1 activating transcription factor 1
BAD BCL2-associated agonist of cell death
BCAR1 breast cancer anti-estrogen resistance 1
BCL2L12 BCL2-like 12 (proline rich)
BID BH3 interacting domain death agonist
BMX BMX non-receptor tyrosine kinase
CDK1 cyclin-dependent kinase 1
CDK2 cyclin-dependent kinase 2
CDK7 cyclin-dependent kinase 7
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1)
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CHEK2 checkpoint kinase 2
CORO1C coronin, actin binding protein, 1C
CSF2RB colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)
CSNK2A1 casein kinase 2, alpha 1 polypeptide
CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa
DAXX death-domain associated protein
DDX5 DEAD (Asp-Glu-Ala-Asp) box helicase 5
DOCK1 dedicator of cytokinesis 1
EGFR epidermal growth factor receptor
FAS Fas cell surface death receptor
FGFR1 fibroblast growth factor receptor 1
FLT1 fms-related tyrosine kinase 1
FOS FBJ murine osteosarcoma viral oncogene homolog
FOXO4 forkhead box O4
GAB1 GRB2-associated binding protein 1
GSK3A glycogen synthase kinase 3 alpha
GSK3B glycogen synthase kinase 3 beta
GSTP1 glutathione S-transferase pi 1
GYS1 glycogen synthase 1 (muscle)
H2AFX H2A histone family, member X
HNRNPA1 heterogeneous nuclear ribonucleoprotein A1
IGFBP3 insulin-like growth factor binding protein 3
IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
JAK2 Janus kinase 2
MAPK1 mitogen-activated protein kinase 1
MAPK3 mitogen-activated protein kinase 3
MTOR mechanistic target of rapamycin (serine/threonine kinase)
MYC v-myc avian myelocytomatosis viral oncogene homolog
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2
PDGFRA platelet-derived growth factor receptor, alpha polypeptide
PDGFRB platelet-derived growth factor receptor, beta polypeptide
PEA15 phosphoprotein enriched in astrocytes 15
PHF20 PHD finger protein 20
PKM pyruvate kinase, muscle
PRKAA1 protein kinase, AMP-activated, alpha 1 catalytic subunit
PRKCI protein kinase C, iota
PRKDC protein kinase, DNA-activated, catalytic polypeptide
PTEN phosphatase and tensin homolog
PTK2 protein tyrosine kinase 2
PXN paxillin
RAF1 Raf-1 proto-oncogene, serine/threonine kinase
RB1 retinoblastoma 1
RBL2 retinoblastoma-like 2
RPS6 ribosomal protein S6
RPS6KB1 ribosomal protein S6 kinase, 70kDa, polypeptide 1
RPTOR regulatory associated protein of MTOR, complex 1
SERPINF1 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1
SMAD1 SMAD family member 1
SMAD5 SMAD family member 5
SMAD9 SMAD family member 9
SRC SRC proto-oncogene, non-receptor tyrosine kinase
STAT3 signal transducer and activator of transcription 3 (acute-phase response factor)
STAT5A signal transducer and activator of transcription 5A
STAT5B signal transducer and activator of transcription 5B
STK4 serine/threonine kinase 4
SYK spleen tyrosine kinase
TP53 tumor protein p53
TSC2 tuberous sclerosis 2
ZAP70 zeta-chain (TCR) associated protein kinase 70kDa